About this item:

385 Views | 501 Downloads

Author Notes:

Rebecca D. Levit, Email: rlevit@emory.edu

The authors of this study would like to thank the Emory Pediatric Flow Cytometry Core, the Emory Personalized Immunotherapy Core, and the Emory Mass Spectrometry Center in Chemistry for their technical support during this project.

Subjects:

Research Funding:

This study was supported by American Heart Association Scientist Development Grant (14SDG18530001) to Levit, and by the National Heart, Lung, and Blood Institute of the NIH under award number T32HL007745 to Shin.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Cardiovascular System & Cardiology
  • cardioprotection
  • cell therapy
  • inflammation
  • ischemia
  • ischemia reperfusion injury
  • mesenchymal stem cell
  • myocardial inflammation
  • ISCHEMIA-REPERFUSION INJURY
  • A(1)/A(2A) RECEPTOR AGONIST
  • VASCULAR SMOOTH-MUSCLE
  • INFARCT SIZE
  • CORONARY ANGIOPLASTY
  • A(2A) RECEPTOR
  • NEUTROPHIL DEPLETION
  • HEART-DISEASE
  • TUMOR-GROWTH
  • STEM-CELLS

Adenosine Production by Biomaterial-Supported Mesenchymal Stromal Cells Reduces the Innate Inflammatory Response in Myocardial Ischemia/Reperfusion Injury

Journal Title:

Journal of the American Heart Association

Volume:

Volume 7, Number 2

Publisher:

, Pages e006949-e006949

Type of Work:

Article | Final Publisher PDF

Abstract:

Background--During myocardial ischemia/reperfusion (MI/R) injury, there is extensive release of immunogenic metabolites that activate cells of the innate immune system. These include ATP and AMP, which upregulate chemotaxis, migration, and effector function of early infiltrating inflammatory cells. These cells subsequently drive further tissue devitalization. Mesenchymal stromal cells (MSCs) are a potential treatment modality for MI/R because of their powerful anti-inflammatory capabilities; however, the manner in which they regulate the acute inflammatory milieu requires further elucidation. CD73, an ecto-50-nucleotidase, may be critical in regulating inflammation by converting pro-inflammatory AMP to anti-inflammatory adenosine. We hypothesized that MSC-mediated conversion of AMP into adenosine reduces inflammation in early MI/R, favoring a micro-environment that attenuates excessive innate immune cell activation and facilitates earlier cardiac recovery. Methods and Results--Adult rats were subjected to 30 minutes of MI/R injury. MSCs were encapsulated within a hydrogel vehicle and implanted onto the myocardium. A subset of MSCs were pretreated with the CD73 inhibitor, a,b-methylene adenosine diphosphate, before implantation. Using liquid chromatography/mass spectrometry, we found that MSCs increase myocardial adenosine availability following injury via CD73 activity. MSCs also reduce innate immune cell infiltration as measured by flow cytometry, and hydrogen peroxide formation as measured by Amplex Red assay. These effects were dependent on MSC-mediated CD73 activity. Finally, through echocardiography we found that CD73 activity on MSCs was critical to optimal protection of cardiac function following MI/R injury. Conclusions--MSC-mediated conversion of AMP to adenosine by CD73 exerts a powerful anti-inflammatory effect critical for cardiac recovery following MI/R injury.

Copyright information:

© 2018 The Authors.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).

Creative Commons License

Export to EndNote